This clinical trial investigates whether a low dose of argipressin (the active substance in REVERPLEG) administered during liver transplantation surgery can help prevent Acute Kidney Injury (AKI), a severe and common post-operative complication.

Participants undergoing the transplant are randomized to receive either the argipressin treatment or a placebo via intravenous infusion. The study concurrently utilizes noradrenaline tartrate (NORADRENALINE VIATRIS) as a comparison or supplementary therapy, reflecting common practice in managing hemodynamic stability.

The core objective is to determine if this proactive use of argipressin can improve patient outcomes by preserving kidney function.

Researchers will closely monitor various health indicators post-surgery, including the incidence and severity of AKI, the requirement for blood transfusions, and the use of other vasoactive medications like norepinephrine.

The results of this study are expected to provide critical, valuable evidence on a potential strategy to reduce the risk of AKI and enhance the overall health and recovery of liver transplant recipients.

Read More